Drug profile · INN
methysergide maleate
SANSERT
methysergide maleate (SANSERT) is a serotonin 1a (5-ht1a) receptor partial agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — methysergide maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
methysergide maleate (SANSERT) is a serotonin 1a (5-ht1a) receptor partial agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 1a (5-HT1a) receptor partial agonist
Primary target: 5-hydroxytryptamine receptor 1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is methysergide maleate?
methysergide maleate (SANSERT) is a serotonin 1a (5-ht1a) receptor partial agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for methysergide maleate?
SANSERT is a marketed brand name for methysergide maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methysergide maleate?
methysergide maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.